Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.70
Bid: 43.10
Ask: 46.90
Change: 0.00 (0.00%)
Spread: 3.80 (8.817%)
Open: 43.70
High: 0.00
Low: 0.00
Prev. Close: 43.70
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive Opinion from the EMA on BMK08

10 Sep 2020 09:15

RNS Number : 6196Y
Benchmark Holdings PLC
10 September 2020
 

10 September 2020

 

Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014.

 

Benchmark Holdings plc

 

Important milestone reached towards commercialisation of BMK08 & CleanTreat®

Positive Opinion from the European Medicine Agency on the safety of BMK08

 

Benchmark, the aquaculture biotechnology business, is pleased to announce that on 10 September 2020 the Committee for Medicinal Products for Veterinary Use ("CVMP"), a committee of the European Medicine Agency, adopted an opinion recommending the inclusion of BMK08's active pharmaceutical ingredient in fin fish as an allowed substance regarding maximum residue limits in foodstuffs of animal origin (the "MRL opinion").

 

The MRL opinion is an important step towards the launch of BMK08 together with the Company's water purification system CleanTreat® in Q2 CY 2021. The MRL opinion is without prejudice to the European Commission's decision and ratification into EU law, which represents the next milestone for BMK08 together with CleanTreat®, and is a condition for obtaining Marketing Authorisation (MA) in Norway.

 

Trond Wiliksen, CEO commented:

 

"The MRL opinion is a significant stepping stone towards the launch of our novel sea lice treatment BMK08, together with CleanTreat® which purifies the treatment water. The positive opinion of the European Medicine Agency's experts in medicine safety is a critical step in a 10-year data collection and assessment process which ensures that the medicine is safe to use and safe for consumers."

 

"I congratulate our teams for getting us to this point and we look forward to making further progress towards a launch in Q2 CY 2021."

 

Enquiries

 

For further information, please contact:

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

MHP Communications

 

Tel: 020 3128 8742

Katie Hunt, Reg Hoare, Alistair de Kare-Silver benchmark@mphc.com

 

 

About Benchmark 

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGIGDCUBBDGGG
Date   Source Headline
19th Feb 202410:59 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
16th Feb 202410:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
15th Feb 20247:00 amRNSQ1 Results
14th Feb 202411:37 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
8th Feb 20244:00 pmRNSResult of AGM
6th Feb 20244:08 pmRNSForm 8.3 - Benchmark Holdings PLC
6th Feb 20247:36 amRNSForm 8.3 - Benchmark Holdings PLC
5th Feb 20245:30 pmRNSRule 2.9 Announcement
5th Feb 20242:50 pmRNSForm 8.3 - Benchmark Holdings PLC
5th Feb 202410:20 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
1st Feb 202410:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
1st Feb 202410:16 amRNSForm 8.3 - Benchmark Holdings plc
31st Jan 20242:03 pmRNSForm 8.3 - Benchmark Holdings
31st Jan 20247:00 amRNSTotal Voting Rights
30th Jan 202411:38 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
29th Jan 202412:18 pmRNSForm 8.3 - Benchmark Holdings plc
26th Jan 20243:19 pmRNSForm 8.3 - Benchmark Holdings Plc - Replacement
26th Jan 202410:48 amRNSForm 8.3 - Benchmark Holdings
26th Jan 20247:00 amRNSForm 8 (OPD) (Benchmark Holdings PLC)
24th Jan 20243:37 pmRNSForm 8.3 - Benchmark Holdings plc - Amendment
24th Jan 20248:46 amRNSForm 8.3 - Benchmark Holdings plc
23rd Jan 20242:40 pmRNSForm 8.3 - Benchmark Holdings Plc
23rd Jan 20242:25 pmRNSForm 8.3 - Benchmark Holdings Plc-Replacement
23rd Jan 20241:57 pmGNWForm 8.3 - [BENCHMARK HOLDINGS PLC - Opening Disclosure - 22 01 2024] - (CGAML)
23rd Jan 202411:20 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
23rd Jan 20247:00 amRNSNotice of Q1 Results
22nd Jan 20246:02 pmRNSRule 2.9 Announcement
22nd Jan 20245:14 pmRNSForm 8.3 - Benchmark Holdings Plc-Replacement
22nd Jan 20244:27 pmRNSForm 8.3 - Benchmark Holdings Plc
22nd Jan 20241:48 pmRNSForm 8.3 -Benchmark Holdings Plc
22nd Jan 20247:00 amRNSStrategic Review and Formal Sale Process
16th Jan 20245:30 pmRNSNotice of AGM - correction
9th Jan 20245:15 pmRNSPosting of Notice of AGM
12th Dec 20235:50 pmRNSNew Long Term Incentive Plan and PDMR Dealing
12th Dec 20231:54 pmRNSDirectorate Change
7th Dec 202312:00 pmRNSPublication of Annual Report and Notice of AGM
29th Nov 20237:01 amRNSDirectorate Change
29th Nov 20237:01 amRNSQ4 Results
29th Nov 20237:00 amRNSFull Year Results
6th Nov 202310:24 amRNSNotice of Q4 and Full Year Results
31st Oct 20237:00 amRNSTotal Voting Rights
10th Oct 202311:26 amRNSNew salmon broodstock licenses - correction
10th Oct 202310:06 amRNSGrant of two new salmon broodstock licenses
29th Sep 20237:00 amRNSTotal Voting Rights
21st Sep 20237:00 amRNSBlock Listing Six Monthly Return
31st Aug 20237:00 amRNSTotal Voting Rights
24th Aug 20237:00 amRNSQ3 Results
11th Aug 20237:00 amRNSNotice of Q3 Results
31st Jul 20237:00 amRNSTotal Voting Rights
30th Jun 20237:00 amRNSAppointment of Non-Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.